Alpha Teknova, Inc. (NASDAQ: TKNO) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $542M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Alpha Teknova, Inc. had a Maz Rating of 3.85 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.14), above most of its sector; its weakest was Valuation (1.66), more expensive than most of its sector. The other factors: Profitability 3.74 (above most of its sector); Growth 3.24 (around the middle of its sector); Financial Health 3.07 (around the middle of its sector). The current rating is for members: log in to see it.
At $8.62, Alpha Teknova, Inc. trades at 11.8x sales and 7.8x book value. Over the last twelve months it generated about $46M of revenue and a net loss of $18M. It runs a gross margin of 35.8%, an operating margin of -32.7% and a net margin of -34.8%. It shows return on equity of -24.9%, return on invested capital of -17.1% and a free cash flow yield of -1.2%. On the balance sheet: a debt-to-equity ratio of 0.45 and a current ratio of 3.56. Over the past 52 weeks the share price ranged from $1.91 to $9.48, with a beta of 0.73.
Alpha Teknova, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.